Mohammod Shahidullah
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mohammod Shahidullah has a total of 177 co-authors. Here are the top co-authors by number of shared publications:
- Abdullah H. Baqui
Department of International Health, International Center for Maternal and Newborn Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA
2 shared publications - Adejumoke Idowu Ayede
Department of Paediatrics, College of Medicine, University of Ibadan and University College Hospital, Ibadan, Nigeria
2 shared publications - Ayesha De Costa
Department of Maternal, Child, and Adolescent Health and Aging, World Health Organization, Geneva, Switzerland
2 shared publications - Chinnathambi Kamalarathnam
Madras Medical College, Chennai, Tamil Nadu, India
2 shared publications - Ebunoluwa Aderonke Adejuyigbe
Department of Paediatrics and Child Health, Obafemi Awolowo University, Ile-Ife, Nigeria
2 shared publications - Fred Were
Department of Paediatrics and Child Health, University of Nairobi, Nairobi, Kenya
2 shared publications
Latest Publications
- Open Access
- 24 July 2026
- Published by Springer Nature in Trials
- Vol. 27 (1) , 510
The World Health Organization Antenatal CorTicosteroids for Improving Outcomes in preterm Newborns (ACTION-III) trial—rationale for the selected lower steroid dose
- 24 July 2026
- Published by Springer Nature in Trials
- Vol. 27 (1) , 510
Open AccessThe World Health Organization Antenatal CorTicosteroids for Improving Outcomes in preterm Newborns (ACTION-III) trial—rationale for the selected lower steroid dose
- Open Access
- 1 January 2025
- Published by Wolters Kluwer Health in Paediatric Nephrology Journal of Bangladesh
- Vol. 10 (1) , 1-3
Medical Ethics in Pediatric and Newborn Practice and Ways of Addressing the Ethical Dilemmas
- 1 January 2025
- Published by Wolters Kluwer Health in Paediatric Nephrology Journal of Bangladesh
- Vol. 10 (1) , 1-3
Open AccessMedical Ethics in Pediatric and Newborn Practice and Ways of Addressing the Ethical Dilemmas
- Open Access
- 29 July 2024
- Published by Bangladesh Academy of Sciences in Bangladesh Journal of Medical Science
- Vol. 23 (3) , 812-817
Outcome of Neonates with Respiratory Distress in a Tertiary Center NICU of Bangladesh: A Prospective Study
Background Respiratory distress in neonatal period is of diverse etiology and require timely diagnosis and treatment for a good outcome. This study was aimed to determine the outcome of neonates having respiratory distress admitted in the NICU of a tertiary care hospital. Methods This prospective study was conducted in the neonatal intensive care unit of Dr. M R Khan Shishu Hospital & ICH, from July 2021 to June 2022. Neonates presented with signs of respiratory distress were enrolled in the study. History, examination and investigations were performed to find out various etiologies. Neonates were managed accordingly and were followed up to hospital stay. Primary outcome was measured in terms of discharge and death, and secondary outcomes were pattern of respiratory supports required. Data was analyzed using SPSS 20. Results Among 1225 admitted newborns, 720 (59%) had respiratory distress. Mean gestational age was 37.54 ± 2.1 weeks and mean birth weight was 2692.96 ± 651 g. Common causes of respiratory distress were sepsis (35.4%) and perinatal asphyxia (27%) followed by transient tachypnea of newborn (11.4%). Most of the babies required only nasal oxygen support (72%) and 15% were treated with CPAP and 8% got mechanical ventilator. Mortality rate was 2.5% and congenital pneumonia was significantly associated with neonatal death (p=0.02). Conclusion The common causes for respiratory distress were sepsis, asphyxia, TTNB, RDS, MAS and congenital pneumonia. Congenital pneumonia was significantly associated with mortality. Bangladesh Journal of Medical Science Vol. 23 No. 03 July’24 Page : 812-817
- 29 July 2024
- Published by Bangladesh Academy of Sciences in Bangladesh Journal of Medical Science
- Vol. 23 (3) , 812-817
Open AccessOutcome of Neonates with Respiratory Distress in a Tertiary Center NICU of Bangladesh: A Prospective Study
Background Respiratory distress in neonatal period is of diverse etiology and require timely diagnosis and treatment for a good outcome. This study was aimed to determine the outcome of neonates having respiratory distress admitted in the NICU of a tertiary care hospital. Methods This prospective study was conducted in the neonatal intensive care unit of Dr. M R Khan Shishu Hospital & ICH, from July 2021 to June 2022. Neonates presented with signs of respiratory distress were enrolled in the study. History, examination and investigations were performed to find out various etiologies. Neonates were managed accordingly and were followed up to hospital stay. Primary outcome was measured in terms of discharge and death, and secondary outcomes were pattern of respiratory supports required. Data was analyzed using SPSS 20. Results Among 1225 admitted newborns, 720 (59%) had respiratory distress. Mean gestational age was 37.54 ± 2.1 weeks and mean birth weight was 2692.96 ± 651 g. Common causes of respiratory distress were sepsis (35.4%) and perinatal asphyxia (27%) followed by transient tachypnea of newborn (11.4%). Most of the babies required only nasal oxygen support (72%) and 15% were treated with CPAP and 8% got mechanical ventilator. Mortality rate was 2.5% and congenital pneumonia was significantly associated with neonatal death (p=0.02). Conclusion The common causes for respiratory distress were sepsis, asphyxia, TTNB, RDS, MAS and congenital pneumonia. Congenital pneumonia was significantly associated with mortality. Bangladesh Journal of Medical Science Vol. 23 No. 03 July’24 Page : 812-817
- Open Access
- 10 May 2024
- Published by BMJ in Archives of Disease in Childhood - Fetal and Neonatal Edition
- Vol. 109 (6) , 594-601
Early and extended erythropoietin monotherapy after hypoxic ischaemic encephalopathy: a multicentre double-blind pilot randomised controlled trial
Objective To examine the feasibility of early and extended erythropoietin monotherapy after hypoxic ischaemic encephalopathy (HIE). Design Double-blind pilot randomised controlled trial. Setting Eight neonatal units in South Asia. Patients Neonates (≥36 weeks) with moderate or severe HIE admitted between 31 December 2022 and 3 May 2023. Interventions Erythropoietin (500 U/kg daily) or to the placebo (sham injections using a screen) within 6 hours of birth and continued for 9 days. MRI at 2 weeks of age. Main outcomes and measures Feasibility of randomisation, drug administration and assessment of brain injury using MRI. Results Of the 154 neonates screened, 56 were eligible; 6 declined consent and 50 were recruited; 43 (86%) were inborn. Mean (SD) age at first dose was 4.4 (1.2) hours in erythropoietin and 4.1 (1.0) hours in placebo. Overall mortality at hospital discharge occurred in 5 (19%) vs 11 (46%) (p=0.06), and 3 (13%) vs 9 (40.9%) (p=0.04) among those with moderate encephalopathy in the erythropoietin and placebo groups. Moderate or severe injury to basal ganglia, white matter and cortex occurred in 5 (25%) vs 5 (38.5%); 14 (70%) vs 11 (85%); and 6 (30%) vs 2 (15.4%) in the erythropoietin and placebo group, respectively. Sinus venous thrombosis was seen in two (10%) neonates in the erythropoietin group and none in the control group. Conclusions Brain injury and mortality after moderate or severe HIE are high in South Asia. Evaluation of erythropoietin monotherapy using MRI to examine treatment effects is feasible in these settings. Trial registration number NCT05395195.
- 10 May 2024
- Published by BMJ in Archives of Disease in Childhood - Fetal and Neonatal Edition
- Vol. 109 (6) , 594-601
Open AccessEarly and extended erythropoietin monotherapy after hypoxic ischaemic encephalopathy: a multicentre double-blind pilot randomised controlled trial
Objective To examine the feasibility of early and extended erythropoietin monotherapy after hypoxic ischaemic encephalopathy (HIE). Design Double-blind pilot randomised controlled trial. Setting Eight neonatal units in South Asia. Patients Neonates (≥36 weeks) with moderate or severe HIE admitted between 31 December 2022 and 3 May 2023. Interventions Erythropoietin (500 U/kg daily) or to the placebo (sham injections using a screen) within 6 hours of birth and continued for 9 days. MRI at 2 weeks of age. Main outcomes and measures Feasibility of randomisation, drug administration and assessment of brain injury using MRI. Results Of the 154 neonates screened, 56 were eligible; 6 declined consent and 50 were recruited; 43 (86%) were inborn. Mean (SD) age at first dose was 4.4 (1.2) hours in erythropoietin and 4.1 (1.0) hours in placebo. Overall mortality at hospital discharge occurred in 5 (19%) vs 11 (46%) (p=0.06), and 3 (13%) vs 9 (40.9%) (p=0.04) among those with moderate encephalopathy in the erythropoietin and placebo groups. Moderate or severe injury to basal ganglia, white matter and cortex occurred in 5 (25%) vs 5 (38.5%); 14 (70%) vs 11 (85%); and 6 (30%) vs 2 (15.4%) in the erythropoietin and placebo group, respectively. Sinus venous thrombosis was seen in two (10%) neonates in the erythropoietin group and none in the control group. Conclusions Brain injury and mortality after moderate or severe HIE are high in South Asia. Evaluation of erythropoietin monotherapy using MRI to examine treatment effects is feasible in these settings. Trial registration number NCT05395195.
- Open Access
- 12 April 2024
- Published by Springer Nature in Trials
- Vol. 25 (1) , 1-15
The World Health Organization Antenatal CorTicosteroids for Improving Outcomes in preterm Newborns (ACTION-III) Trial: study protocol for a multi-country, multi-centre, double-blind, three-arm, placebo-controlled, individually randomized trial of antenatal corticosteroids for women at high probability of late preterm birth in hospitals in low- resource countries
Background: Preterm birth complications are the leading cause of newborn and under-5 mortality. Over 85% of all preterm births occur in the late preterm period, i.e. between 34 and < 37 weeks of gestation. Antenatal corticosteroids (ACS) prevent mortality and respiratory morbidity when administered to women at high risk of an early preterm birth, i.e. < 34 weeks’ gestation. However, the benefits and risks of ACS in the late preterm period are less clear; both guidelines and practices vary between settings. Emerging evidence suggests that the benefits of ACS may be achievable at lower doses than presently used. This trial aims to determine the efficacy and safety of two ACS regimens compared to placebo, when given to women with a high probability of late preterm birth, in hospitals in low-resource countries. Methods: WHO ACTION III trial is a parallel-group, three-arm, individually randomized, double-blind, placebo-controlled trial of two ACS regimens: dexamethasone phosphate 4 × 6 mg q12h or betamethasone phosphate 4 × 2 mg q 12 h. The trial is being conducted across seven sites in five countries—Bangladesh, India, Kenya, Nigeria, and Pakistan. Eligible women are those with a gestational age between 34 weeks 0 days and 36 weeks 5 days, who have a high probability of preterm birth between 12 h and 7 days (up to 36 weeks 6 days gestation). The primary outcome is a composite of stillbirth or neonatal death within 72 h of birth or use of newborn respiratory support within 72 h of birth or prior to discharge from hospital, whichever is earlier. Secondary outcomes include safety and health utilization measures for both women and newborns. The sample size is 13,500 women. Discussion: This trial will evaluate the benefits and possible harms of ACS when used in women likely to have a late preterm birth. It will also evaluate a lower-dose ACS regimen based on literature from pharmacokinetic studies. The results of this trial will provide robust critical evidence on the safe and appropriate use of ACS in the late preterm period internationally. Trial registration: ISRCTN11434567. Registered on 7 June 2021.
- 12 April 2024
- Published by Springer Nature in Trials
- Vol. 25 (1) , 1-15
Open AccessThe World Health Organization Antenatal CorTicosteroids for Improving Outcomes in preterm Newborns (ACTION-III) Trial: study protocol for a multi-country, multi-centre, double-blind, three-arm, placebo-controlled, individually randomized trial of antenatal corticosteroids for women at high probability of late preterm birth in hospitals in low- resource countries
Background: Preterm birth complications are the leading cause of newborn and under-5 mortality. Over 85% of all preterm births occur in the late preterm period, i.e. between 34 and < 37 weeks of gestation. Antenatal corticosteroids (ACS) prevent mortality and respiratory morbidity when administered to women at high risk of an early preterm birth, i.e. < 34 weeks’ gestation. However, the benefits and risks of ACS in the late preterm period are less clear; both guidelines and practices vary between settings. Emerging evidence suggests that the benefits of ACS may be achievable at lower doses than presently used. This trial aims to determine the efficacy and safety of two ACS regimens compared to placebo, when given to women with a high probability of late preterm birth, in hospitals in low-resource countries. Methods: WHO ACTION III trial is a parallel-group, three-arm, individually randomized, double-blind, placebo-controlled trial of two ACS regimens: dexamethasone phosphate 4 × 6 mg q12h or betamethasone phosphate 4 × 2 mg q 12 h. The trial is being conducted across seven sites in five countries—Bangladesh, India, Kenya, Nigeria, and Pakistan. Eligible women are those with a gestational age between 34 weeks 0 days and 36 weeks 5 days, who have a high probability of preterm birth between 12 h and 7 days (up to 36 weeks 6 days gestation). The primary outcome is a composite of stillbirth or neonatal death within 72 h of birth or use of newborn respiratory support within 72 h of birth or prior to discharge from hospital, whichever is earlier. Secondary outcomes include safety and health utilization measures for both women and newborns. The sample size is 13,500 women. Discussion: This trial will evaluate the benefits and possible harms of ACS when used in women likely to have a late preterm birth. It will also evaluate a lower-dose ACS regimen based on literature from pharmacokinetic studies. The results of this trial will provide robust critical evidence on the safe and appropriate use of ACS in the late preterm period internationally. Trial registration: ISRCTN11434567. Registered on 7 June 2021.
- Open Access
- 3 November 2019
- Published by Bangladesh Academy of Sciences in Bangladesh Journal of Medical Science
- Vol. 19 (1) , 133-140
Risk Factors and Complications of Newborns with Birth Defect: A Hospital based Case-Control Study
Background: Birth defect is one of the most important causes of neonatal mortality worldwide. In a developing country like Bangladesh many possible factors for birth defects are present which should be identified. This study was performed to determine those risk factors of birth defect and complications associated with it. Materials and Methods: A hospital based matched case-control study was conducted from August 2015 to July 2016 in department of Neonatology along with Obstetrics and Gynecology at BSMMU. A total of 98 mother-infant pair (49 babies with birth defect as cases and 49 healthy babies without any birth defects as controls) was included in the study. For each case, a gestational age, sex and post-natal age matched control was taken. Data was collected by face to face interview. Univariate and multivariate conditional logistic regression models were computed to examine the effect of independent variables on outcome variable using SPSS 23.0. Variables with p-value Results: The mean (± SD) birth weight for cases and controls were 2718.37 (±756.9) grams, and 2617.14 (±978.8) grams respectively. Cardiovascular system was the predominant system (21%) involved in birth defects. Maternal age between 20-29 years (AOR: 4.69; 95% CI 1.078, 20.448), less than four antenatal care visits (AOR: 10.07; 95% CI 2.816, 36.0), no multivitamin intake (AOR: 7.38; 95% CI 1.791, 30.365) and presence of maternal diabetes (AOR: 0.194; 95% CI 0.047, 0.799) were significantly associated with birth defects among newborns. Sepsis, asphyxia, hypoglycemia and dyselectrolytemia were the most prevalent problems among these babies. The need of intravenous fluid, thermal care, antibiotics and mechanical ventilation was also high among the cases. Conclusion: Birth defect is an upcoming issue in current newborn health situation which need to be prioritized. Significant risk factors should be addressed timely for early diagnosis and proper management of these babies can help in reduction of mortality. Bangladesh Journal of Medical Science Vol.19(1) 2020 p.133-140
- 3 November 2019
- Published by Bangladesh Academy of Sciences in Bangladesh Journal of Medical Science
- Vol. 19 (1) , 133-140
Open AccessRisk Factors and Complications of Newborns with Birth Defect: A Hospital based Case-Control Study
Background: Birth defect is one of the most important causes of neonatal mortality worldwide. In a developing country like Bangladesh many possible factors for birth defects are present which should be identified. This study was performed to determine those risk factors of birth defect and complications associated with it. Materials and Methods: A hospital based matched case-control study was conducted from August 2015 to July 2016 in department of Neonatology along with Obstetrics and Gynecology at BSMMU. A total of 98 mother-infant pair (49 babies with birth defect as cases and 49 healthy babies without any birth defects as controls) was included in the study. For each case, a gestational age, sex and post-natal age matched control was taken. Data was collected by face to face interview. Univariate and multivariate conditional logistic regression models were computed to examine the effect of independent variables on outcome variable using SPSS 23.0. Variables with p-value Results: The mean (± SD) birth weight for cases and controls were 2718.37 (±756.9) grams, and 2617.14 (±978.8) grams respectively. Cardiovascular system was the predominant system (21%) involved in birth defects. Maternal age between 20-29 years (AOR: 4.69; 95% CI 1.078, 20.448), less than four antenatal care visits (AOR: 10.07; 95% CI 2.816, 36.0), no multivitamin intake (AOR: 7.38; 95% CI 1.791, 30.365) and presence of maternal diabetes (AOR: 0.194; 95% CI 0.047, 0.799) were significantly associated with birth defects among newborns. Sepsis, asphyxia, hypoglycemia and dyselectrolytemia were the most prevalent problems among these babies. The need of intravenous fluid, thermal care, antibiotics and mechanical ventilation was also high among the cases. Conclusion: Birth defect is an upcoming issue in current newborn health situation which need to be prioritized. Significant risk factors should be addressed timely for early diagnosis and proper management of these babies can help in reduction of mortality. Bangladesh Journal of Medical Science Vol.19(1) 2020 p.133-140
- Open Access
- 10 August 2018
- Published by Springer Nature in BMC Genetics
- Vol. 19 (1) , 58
High resolution melting curve analysis enables rapid and reliable detection of G6PD variants in heterozygous females
Like glucose-6-phosphate dehydrogenase (G6PD) deficient hemizygous males and homozygous females, heterozygous females could also manifest hemolytic crisis, neonatal hyperbilirubinemia or kernicterus upon exposure to oxidative stress induced by certain foods such as fava beans, drugs or infections. Although hemizygous males and homozygous females are easily detected by conventional G6PD enzyme assay method, the heterozygous state could be missed by the conventional methods as the mosaic population of both normal and deficient RBCs circulates in the blood. Thus the present study aimed to apply high resolution melting (HRM) curve analysis approach to see whether HRM could be used as a supplemental approach to increase the chance of detection of G6PD heterozygosity. Sixty-three clinically suspected females were evaluated for G6PD status using both enzyme assay and HRM analysis. Four out of sixty-three participants came out as G6PD deficient by the enzyme assay method, whereas HRM approach could identify nine participants with G6PD variants, one homozygous and eight heterozygous. Although only three out of eight heterozygous samples had G6PD enzyme deficiency, the HRM-based heterozygous G6PD variants detection for the rest of the samples with normal G6PD enzyme activities could have significance because their newborns might fall victim to serious consequences under certain oxidative stress. In addition to the G6PD enzyme assay, HRM curve analysis could be useful as a supplemental approach for detection of G6PD heterozygosity.
- 10 August 2018
- Published by Springer Nature in BMC Genetics
- Vol. 19 (1) , 58
Open AccessHigh resolution melting curve analysis enables rapid and reliable detection of G6PD variants in heterozygous females
Like glucose-6-phosphate dehydrogenase (G6PD) deficient hemizygous males and homozygous females, heterozygous females could also manifest hemolytic crisis, neonatal hyperbilirubinemia or kernicterus upon exposure to oxidative stress induced by certain foods such as fava beans, drugs or infections. Although hemizygous males and homozygous females are easily detected by conventional G6PD enzyme assay method, the heterozygous state could be missed by the conventional methods as the mosaic population of both normal and deficient RBCs circulates in the blood. Thus the present study aimed to apply high resolution melting (HRM) curve analysis approach to see whether HRM could be used as a supplemental approach to increase the chance of detection of G6PD heterozygosity. Sixty-three clinically suspected females were evaluated for G6PD status using both enzyme assay and HRM analysis. Four out of sixty-three participants came out as G6PD deficient by the enzyme assay method, whereas HRM approach could identify nine participants with G6PD variants, one homozygous and eight heterozygous. Although only three out of eight heterozygous samples had G6PD enzyme deficiency, the HRM-based heterozygous G6PD variants detection for the rest of the samples with normal G6PD enzyme activities could have significance because their newborns might fall victim to serious consequences under certain oxidative stress. In addition to the G6PD enzyme assay, HRM curve analysis could be useful as a supplemental approach for detection of G6PD heterozygosity.
- Open Access
- 18 September 2017
- Published by Springer Nature in Trials
- Vol. 18 (1) , 1-14
Hypothermia for encephalopathy in low and middle-income countries (HELIX): study protocol for a randomised controlled trial
Therapeutic hypothermia reduces death and disability after moderate or severe neonatal encephalopathy in high-income countries and is used as standard therapy in these settings. However, the safety and efficacy of cooling therapy in low- and middle-income countries (LMICs), where 99% of the disease burden occurs, remains unclear. We will examine whether whole body cooling reduces death or neurodisability at 18–22 months after neonatal encephalopathy, in LMICs. We will randomly allocate 408 term or near-term babies (aged ≤ 6 h) with moderate or severe neonatal encephalopathy admitted to public sector neonatal units in LMIC countries (India, Bangladesh or Sri Lanka), to either usual care alone or whole-body cooling with usual care. Babies allocated to the cooling arm will have core body temperature maintained at 33.5 °C using a servo-controlled cooling device for 72 h, followed by re-warming at 0.5 °C per hour. All babies will have detailed infection screening at the time of recruitment and 3 Telsa cerebral magnetic resonance imaging and spectroscopy at 1–2 weeks after birth. Our primary endpoint is death or moderate or severe disability at the age of 18 months. Upon completion, HELIX will be the largest cooling trial in neonatal encephalopathy and will provide a definitive answer regarding the safety and efficacy of cooling therapy for neonatal encephalopathy in LMICs. The trial will also provide important data about the influence of co-existent perinatal infection on the efficacy of hypothermic neuroprotection. ClinicalTrials.gov, NCT02387385 . Registered on 27 February 2015.
- 18 September 2017
- Published by Springer Nature in Trials
- Vol. 18 (1) , 1-14
Open AccessHypothermia for encephalopathy in low and middle-income countries (HELIX): study protocol for a randomised controlled trial
Therapeutic hypothermia reduces death and disability after moderate or severe neonatal encephalopathy in high-income countries and is used as standard therapy in these settings. However, the safety and efficacy of cooling therapy in low- and middle-income countries (LMICs), where 99% of the disease burden occurs, remains unclear. We will examine whether whole body cooling reduces death or neurodisability at 18–22 months after neonatal encephalopathy, in LMICs. We will randomly allocate 408 term or near-term babies (aged ≤ 6 h) with moderate or severe neonatal encephalopathy admitted to public sector neonatal units in LMIC countries (India, Bangladesh or Sri Lanka), to either usual care alone or whole-body cooling with usual care. Babies allocated to the cooling arm will have core body temperature maintained at 33.5 °C using a servo-controlled cooling device for 72 h, followed by re-warming at 0.5 °C per hour. All babies will have detailed infection screening at the time of recruitment and 3 Telsa cerebral magnetic resonance imaging and spectroscopy at 1–2 weeks after birth. Our primary endpoint is death or moderate or severe disability at the age of 18 months. Upon completion, HELIX will be the largest cooling trial in neonatal encephalopathy and will provide a definitive answer regarding the safety and efficacy of cooling therapy for neonatal encephalopathy in LMICs. The trial will also provide important data about the influence of co-existent perinatal infection on the efficacy of hypothermic neuroprotection. ClinicalTrials.gov, NCT02387385 . Registered on 27 February 2015.
- Open Access
- 20 August 2017
- Published by Bangladesh Academy of Sciences in Bangladesh Journal of Child Health
- Vol. 41 (1) , 34-39
Perinatal Characteristics and Outcome of Neonates at NICU of a Tertiary Level Hospital in Bangladesh
Background: One of the Millennium Development Goals (MDG-4) is to reduce child mortality up to two-thirds by 2015. In most developing countries, a higher proportion of neonatal deaths are observed. It has been recognized that without a substantial reduction in neonatal deaths, MDG-4 will not be met. Objective: To assess the perinatal characteristics, pattern of admissions and outcome of neonates in a tertiary care centre in Bangladesh. Methods: A retrospective review of consecutive neonatal admissions to Bangabandhu Sheikh Mujib Medical University, between January and December 2013, was conducted. Data were collected from the neonatal admission, discharge and death registers. Standard definitions of the conditions were used to diagnose the clinical conditions. Results: Total 683 neonates were admitted to the NICU. Among them 56.1% were inborn and males were 56.8%. Total 61.3% neonates were low birth weight and 60.3 % were preterm. The overall cesarean section rate was 61.9%. Total 35.3% neonates had sepsis and perinatal asphyxia was present in 16.8% neonates. Congenital anomaly was present in 17.6% neonates. The mean duration of hospital stay was 11.1 days and overall mortality rate was 14.9%. Conclusion: Prematurity, neonatal infections, birth asphyxia and congenital anomalies were the main causes of neonatal hospital admission and neonatal deaths in this study. Bangladesh J Child Health 2017; VOL 41 (1) :34-39
- 20 August 2017
- Published by Bangladesh Academy of Sciences in Bangladesh Journal of Child Health
- Vol. 41 (1) , 34-39
Open AccessPerinatal Characteristics and Outcome of Neonates at NICU of a Tertiary Level Hospital in Bangladesh
Background: One of the Millennium Development Goals (MDG-4) is to reduce child mortality up to two-thirds by 2015. In most developing countries, a higher proportion of neonatal deaths are observed. It has been recognized that without a substantial reduction in neonatal deaths, MDG-4 will not be met. Objective: To assess the perinatal characteristics, pattern of admissions and outcome of neonates in a tertiary care centre in Bangladesh. Methods: A retrospective review of consecutive neonatal admissions to Bangabandhu Sheikh Mujib Medical University, between January and December 2013, was conducted. Data were collected from the neonatal admission, discharge and death registers. Standard definitions of the conditions were used to diagnose the clinical conditions. Results: Total 683 neonates were admitted to the NICU. Among them 56.1% were inborn and males were 56.8%. Total 61.3% neonates were low birth weight and 60.3 % were preterm. The overall cesarean section rate was 61.9%. Total 35.3% neonates had sepsis and perinatal asphyxia was present in 16.8% neonates. Congenital anomaly was present in 17.6% neonates. The mean duration of hospital stay was 11.1 days and overall mortality rate was 14.9%. Conclusion: Prematurity, neonatal infections, birth asphyxia and congenital anomalies were the main causes of neonatal hospital admission and neonatal deaths in this study. Bangladesh J Child Health 2017; VOL 41 (1) :34-39
- Open Access
- 13 February 2017
- Published by Bangladesh Academy of Sciences in Bangladesh Journal of Child Health
- Vol. 40 (1) , 1-4
Ethics in Medical Practice
Not available Bangladesh J Child Health 2016; VOL 40 (1) :1-4
- 13 February 2017
- Published by Bangladesh Academy of Sciences in Bangladesh Journal of Child Health
- Vol. 40 (1) , 1-4
Open AccessEthics in Medical Practice
Not available Bangladesh J Child Health 2016; VOL 40 (1) :1-4